Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.

ABSTRACT: Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable

SUBMITTER: Casulo C 

PROVIDER: S-EPMC9974165 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature